ViraTherapeutics GmbH logo

ViraTherapeutics GmbH

ViraTherapeutics develops a new class of immunotherapy drugs based on oncolytic (cancer-destroying) viruses. Our patent protected virus is designed to be safe for human beings and efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for our modified Vesicular Stomatitis Virus (VSV-GP) and aims to conduct first clinical trials in cancer patients in the near future.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.viratherapeutics.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Exlgasse 20a 6020
Innsbruck
Austria
Email
Contact Number
+43 512 272061

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/viral-therapeutics-inc” connections=”true” suffix=””]

ViraTherapeutics proprietary oncolytic virus VSV-GP is extremely rapid and efficient in killing human cancer cells having life cycle of six to eight hours, also VSV-GP is non-neurotoxic and safe as it does not integrate into host genome.

In Sep 2016, ViraTherapeutics and Boehringer Ingelheim signed long term collaboration to jointly develop a next generation oncolytic virus therapy platform and to investigate ViraTherapeutics lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) glycoprotein (GP)) alone and in combination with other therapies. The total potential of deal was Euro 210 Mn, with Boehringer Ingelheim has an option to acquire ViraTherapeutics after conclusion of Ph I clinical trials.
Further. in March 2018, ViraTherapeutics, expand the collaboration with Boehringer Ingelheim, with a second oncolytic virus program, stemming from ViraTherapeutics technology platform utilizing the Vesicular Stomatitis Virus (VSV)armed with an additional immunotherapeutic component from Boehringer Ingelheim, and will cover all R&D costs for the program. Further financial remains undisclosed.

In June 2015, ViraTherapeutics raised ã3.6 Mn in Series A. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF) and EMBL Ventures, and included an investment from Austria Wirtschaftsservice (aws) through its Venture-Capital-Initiative.